Caphorn is now part of Anaxago Group to become a leader in alternative investment.


Osivax is a phase II clinical-stage biotech company transforming the vaccine development landscape through its proprietary oligoDOM® technology platform and universal vaccine candidates designed to provide long-term protection against highly mutating viruses.

Other Companies in our Portfolio